Abstracts von Vorträgen (Peer-Reviewed) Andreeva E, Geissler N, Gutenbrunner C. Entwicklung eines Testmanuals für arbeitsbezogene Leistungsdiagnostik mit dem Sapphire-System. DRV-Schriften 2018; 113: 45-47
Tacke F, Chavan A, Länger F, Klempnauer J, Manns MP: Yersinia infection mimicking recurrence of gastrointestinal stromal tumor. Scand J Gastroenterol 2004; 39(6): 609-12 Martin JH, Potthoff A, Ledig S, Cornberg
Wasielewski R, Mengel M, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H: Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis
, Bumann, D., Herbrand, H., Willer, Y., Dahne, S., Forster, R., and Pabst, O. (2007). Solitary intestinal lymphoid tissue provides a productive port of entry for Salmonella enterica serovar Typhimurium
1182/bloodadvances.2018016501. PMID: 29540340 Free PMC article. Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases. Balduini [...] 10.1016/j.ejmg.2018.01.014. Epub 2018 Mar 13. PMID: 29545013 Review. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Simeoni I, Stephens JC, Hu
outcomes and patient safety. Today, antimicrobial therapy is mostly based on phenotypic resistance testing (antibiograms). We aim to contribute to the digital revolution in microbiology diagnostics by integrating
Josenhans C. Functional expression of TLR5 of different vertebrate species and diversification in intestinal pathogen recognition. Sci Rep 2018; 8(1):11287. Fleissner F, Salman J, Naqizadah J, Avsar M, Meier
Conference, Lyon, September 2015 Paper No. IRC-15-11 What is the Benefit of the Frontal Mobile Barrier Test Procedure? Adolph T., Ott J., Eickhoff B., Johannsen H. ESV Conference, Gothenburg, June 2015 Paper
ermöglichen, in den nächsten zwei Jahren unterschiedliche anti-entzündliche Medikamente im Modell zu testen, um zu entscheiden, welche Medikamente sich für die Anwendung bei Patienten mit Mukoviszidose besonders
imbalance und der zugrundeliegenden Mechanismen zu erforschen und um mögliche therapeutische Ansätze zu testen, arbeiten wir darüber hinaus an der Generierung eines genomeditierten Schweins mittels CRISPR/Cas9